Clinical Trial Update: Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma [Phase 1]

View source ↗

Summary

DCR-MYC, an investigational therapy, was evaluated in a Phase I multicenter dose-escalation study in patients with solid tumors, multiple myeloma, and lymphoma.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-hodgkin Lymphoma
• Pancreatic Neuroendocrine Tumor
• Solid Tumors

Drugs mentioned

• DCR-MYC

Snippet

Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Conditions: Solid Tumors, Multiple Myeloma | Phase 1 | Status: TERMINATED